Navigation Links
Stopping ovarian cancer by blocking proteins coded by notorious gene
Date:12/15/2008

Ovarian cancer cells are "addicted" to a family of proteins produced by the notorious oncogene, MYC, and blocking these Myc proteins halts cell proliferation in the deadliest cancer of the female reproductive system, according to a presentation by University of California, Berkeley scientists at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.

In 30-60 percent of human ovarian tumors, MYC is overly active, or amplified, usually as a result of extra chromosomal copies of the cancer-causing gene.

The extra MYC encourages the ovarian cells to manufacture too much c-Myc, a protein that regulates other genes involved in cellular growth and proliferation.

The presence of excessive c-Myc protein drives healthy cells down the cancer development pathway.

Using RNA interference (RNAi) to block c-Myc protein, Berkeley scientists, Tulsiram Prathapam and G. Steven Martin, treated lab cultures of human ovarian cancer cells that contained amplified MYC. RNAi's blocking of the c-Myc protein stopped the cancer cell cycle in its tracks.

But RNAi blocking of c-Myc protein in lab cultures in which the MYC gene was not experimentally amplified did not affect ovarian cancer cell growth.

The scientists suspect that even when c-Myc was blocked in non-amplified cells, other forms of the protein ⎯ L-Myc and N-Myc ⎯ likely were present and continued to maintain cell proliferation.

By using small interfering RNA (siRNA) to silence L-Myc and N-Myc, the researchers succeeded in shutting down the growth of the non-amplified MYC tumors.

These therapies also were applied to lab cultures of normal ovarian surface epithelial cells. Blocking all the Myc proteins in the normal cultures did not affect cell proliferation, perhaps because the RNAi and siRNA "therapies" are effective only when the MYC genes are abnormally active.

The scientists hope that their results may lead to a new approach to treating ovarian cancer, the most lethal cancer of the female reproductive system. The American Cancer Society predicts that in 2008, 21,650 new cases of ovarian cancer and 15,520 deaths from this form of cancer will occur. In comparison, cervical cancer will affect almost twice as many new cases -- 40,000 -- but fewer than half as many deaths ⎯ 7,470. According to the trends in mortality charted by the National Cancer Institute, cervical cancer deaths fell 3.4 percent while ovarian cancer deaths declined by only 0.2 percent from 1996 to 2005.


'/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814
American Society for Cell Biology
Source:Eurekalert

Related medicine news :

1. Stopping Statins After Stroke Doubles Death Risk
2. Stopping Tysabri May Worsen MS
3. On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack
4. Hands2GO(R) Hand Sanitizer Offers Alcohol-Free Alternative to Stopping the Spread of Flu at School and Work
5. Common drug for stopping preterm labor may be harmful for babies
6. New Sedona Stopping Diabetes Program
7. New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Familys Feet
8. First 90 Days After Stopping Plavix Most Dangerous
9. Physicians focus on stopping pain epidemic
10. Fugitive cancer cells can be blocked by stopping blood cells that aid them
11. Stopping a receptor called nogo boosts the synapses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle ... in Jefferson County, is announcing the launch of a charity drive to raise ... of homeless women and children in Birmingham has grown steadily since the 1980’s, ...
(Date:12/8/2016)... ... 08, 2016 , ... The Compretta Insurance Agency, a family owned insurance and ... the Hancock County area, is announcing the launch of a charity effort aimed at ... County Food Pantry has worked for more than 30 years to meet the food ...
(Date:12/7/2016)... OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... clinical trials with the announcement that it is one of the early adopters completing ... Privacy Shield Framework is designed to provide companies on both sides of the Atlantic ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry leader ... through a new partnership with Splashtop Inc. This remote control for Android extends ... help businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise mobility ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- Boehringer Ingelheim announced today that it has been recognized ... the ninth time that the company received a perfect ... to Work for LGBT Equality. Administered by the Human ... report on corporate policies and practices related to workplace ... "We are committed to creating an ...
(Date:12/8/2016)... , Dec. 8, 2016  Avelas Biosciences, ... improving cancer patient care from diagnosis through treatment, ... recently completed Phase 1b study in breast cancer ... San Antonio Breast Cancer Symposium. Jonathan Unkart ... at UC San Diego Health, delivered the presentation ...
(Date:12/8/2016)... 2016  Hanson Research, an innovative leader in ... diffusion testing instruments for the pharmaceutical industry, announced ... Inc. ("Teledyne"). The move is designed to deepen ... instruments, as well as expand resources for further ... and services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
Breaking Medicine Technology: